Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Inhibitors of the mutant isocitrate dehydrogenase 1 (IDH1) entered recently in clinical trials for glioma treatment. Mutant IDH1 produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene expression. In this study, we show the initial evi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Nat Commun
Главные авторы: Andronesi, Ovidiu C., Arrillaga-Romany, Isabel C., Ly, K. Ina, Bogner, Wolfgang, Ratai, Eva M., Reitz, Kara, Iafrate, A. John, Dietrich, Jorg, Gerstner, Elizabeth R., Chi, Andrew S., Rosen, Bruce R., Wen, Patrick Y., Cahill, Daniel P., Batchelor, Tracy T.
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5902553/
https://ncbi.nlm.nih.gov/pubmed/29662077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03905-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы